Your browser doesn't support javascript.
loading
Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer.
Mack, Philip C; Hsu, Chih-Yuan; Rodilla, Ananda M; Gomez, Jorge E; Cagan, Jazz; Huang, Yuanhui; Tavolacci, Sooyun; Valanparambil, Rajesh M; Rohs, Nicholas; Brody, Rachel; Nichols, Brittney; Carreño, Juan Manuel; Bhalla, Sheena; Rolfo, Christian; Gerber, David E; Moore, Amy; King, Jennifer C; Ahmed, Rafi; Minna, John D; Bunn, Paul A; García-Sastre, Adolfo; Krammer, Florian; Hirsch, Fred R; Shyr, Yu.
Afiliação
  • Mack PC; Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Hsu CY; Department of Biostatistics, Vanderbilt University, Nashville, TN 37235, USA.
  • Rodilla AM; Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Gomez JE; Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Cagan J; Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Huang Y; Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Tavolacci S; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Valanparambil RM; Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Rohs N; Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA.
  • Brody R; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA.
  • Nichols B; Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Carreño JM; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Bhalla S; GO2 Foundation for Lung Cancer, Washington, DC 20006, USA.
  • Rolfo C; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Gerber DE; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Moore A; Hamon Center for Therapeutic Oncology Research, Departments of Internal Medicine and Pharmacology UT Southwestern Medical Center, Dallas, TX 75235, USA.
  • King JC; Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Ahmed R; Hamon Center for Therapeutic Oncology Research, Departments of Internal Medicine and Pharmacology UT Southwestern Medical Center, Dallas, TX 75235, USA.
  • Minna JD; LUNGevity Foundation, Bethesda, MD 20814, USA.
  • Bunn PA; GO2 Foundation for Lung Cancer, Washington, DC 20006, USA.
  • García-Sastre A; Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA.
  • Krammer F; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA.
  • Hirsch FR; Hamon Center for Therapeutic Oncology Research, Departments of Internal Medicine and Pharmacology UT Southwestern Medical Center, Dallas, TX 75235, USA.
  • Shyr Y; Department of Internal Medicine, University of Colorado Cancer Center, Denver, CO 80045, USA.
Vaccines (Basel) ; 12(7)2024 Jun 26.
Article em En | MEDLINE | ID: mdl-39066351
ABSTRACT
In patients with lung cancer (LC), understanding factors that impact the dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike antibody (SAb) titers over time is critical, but challenging, due to evolving treatments, infections, vaccinations, and health status. The objective was to develop a time-dependent regression model elucidating individual contributions of factors influencing SAb levels in LC patients using a prospective, longitudinal, multi-institutional cohort study initiated in January 2021. The study evaluated 296 LC patients-median age 69; 55% female; 50% stage IV. Blood samples were collected every three months to measure SAb levels using FDA-approved ELISA. Asymptomatic and unreported infections were documented through measurement of anti-nucleocapsid Ab levels (Meso Scale Discovery). Associations between clinical characteristics and titers were evaluated using a time-dependent linear regression model with a generalized estimating equation (GEE), considering time-independent variables (age, sex, ethnicity, smoking history, histology, and stage) and time-dependent variables (booster vaccinations, SARS-CoV-2 infections, cancer treatment, steroid use, and influenza vaccination). Significant time-dependent effects increasing titer levels were observed for prior SARS-CoV-2 infection (p < 0.001) and vaccination/boosters (p < 0.001). Steroid use (p = 0.043) and chemotherapy (p = 0.033) reduced titer levels. Influenza vaccination was associated with increased SAb levels (p < 0.001), independent of SARS-CoV-2 vaccine boosters. Prior smoking significantly decreased titers in females (p = 0.001). Age showed no association with titers. This GEE-based linear regression model unveiled the nuanced impact of multiple variables on patient anti-spike Ab levels over time. After controlling for the major influences of vaccine and SARS-CoV-2 infections, chemotherapy and steroid use were found to have negatively affected titers. Smoking in females significantly decreased titers. Surprisingly, influenza vaccinations were also significantly associated, likely indirectly, with improved SARS-CoV-2 titers.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article